Skip to main content

Table 3 Estimated study- treatment-, time- and individual covariate- effects using a fixed effect model

From: Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations

Parameters

mean

sd

2.5%

97.5%

α 1

4.91*

0.71

3.61

6.42

α 2

5.77*

0.72

4.45

7.29

γ S 3 (Study 3-1)

0.246

0.537

-0.742

1.371

γ S 4 (Study 4-1)

0.572

0.584

−0.547

1.719

γ S 5 (Study 5-1)

−0.505

0.367

−1.216

0.222

γ 2 (AQ)

−0.402

0.434

−1.218

0.481

γ 3 (AMLM)

1.212

0.936

−0.443

3.24

γ 4 (ASCD)

−1.514*

0.682

−2.85

−0.186

γ 5 (ASSP)

−0.109

0.465

−0.989

0.844

γ 6 (DHPP)

2.353*

0.852

0.924

4.288

γ D 21 (Day 21–14)

−2.121*

0.459

−3.112*

−1.298

γ D 28 (Day 28–14)

−2.036*

0.467

−3.030*

−1.194

Weight

0.218

0.360

−0.478

0.933

Gender

−0.154

0.234

−0.615

0.298

Age

0.189

0.505

−0.896

1.067

Parasitaemia Day 0

−0.171

0.352

−0.872

0.506

Parasitaemia Day 3

0.085

0.669

−1.083

1.542

Expected children

795

746

732

 

Missing

49

14

59

122 (15)

Fully observed

746

732

687

 
  1. sd: standard deviation, 2.5% and 97.5% : percentiles of the posterior distributions. Study reference: Study 1; Treatment reference: ASAQ; Day reference: Day 14. *: significant effect at the 0.05% level.